Vasoactive intestinal peptide (VIP) is a 28 amino acid peptide (human, chr 6q26-q27). It is expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a MW of 20kD. VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder. VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein). VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family. The VIP is 100% conserved in mouse, rat and human. VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with down regulation of both inflammatory and autoimmune components of the disease.
Species Sequence Homology:rat, human and mouse, 100%
Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for Western Blot due to low molecular weight. Other applications not tested.
Recommended Dilutions:ELISA: 1ug/ml to coat ELISA plates when using V2115-01 (0.5-1ug/ml). Antibody Blocking: 5-10ug/ 1ug V2115-01Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
